Castle Biosciences Says New Data Supporting The Utility Of Its DecisionDx-SCC Test In Patients With High-risk Cutaneous Squamous Cell Carcinoma Tumors Located On The Head And Neck (H&N) Will Be Shared At 56Th American College Of MOHS Surgery Meeting
Castle Biosciences Says New Data Supporting The Utility Of Its DecisionDx-SCC Test In Patients With High-risk Cutaneous Squamous Cell Carcinoma Tumors Located On The Head And Neck (H&N) Will Be Shared At 56Th American College Of MOHS Surgery Meeting
Castle Biosciences表示，支持其DecisionDX-SCC測試在頭頸部（H＆N）高風險皮膚鱗狀細胞癌患者中的實用性的新數據將在第56屆美國衛生部外科學會會議上分享
Castle Biosciences Says New Data Supporting The Utility Of Its DecisionDx-SCC Test In Patients With High-risk Cutaneous Squamous Cell Carcinoma Tumors Located On The Head And Neck (H&N) Will Be Shared At 56Th American College Of MOHS Surgery Meeting
Castle Biosciences表示，支持其DecisionDX-SCC測試在頭頸部（H＆N）高風險皮膚鱗狀細胞癌患者中的實用性的新數據將在第56屆美國衛生部外科學會會議上分享
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。